Products & Tech | Page 30 of 63

Takeda Receives Positive Opinion from EU on Three New Diabetes Treatments

The Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has issued a positive opinion for three new…

AstraZeneca and Bristol-Myers Squibb Resubmit New Type 2 Diabetes Treatment for FDA Approval

AstraZeneca and Bristol-Myers Squibb Company resubmitted a New Drug Application (NDA) to the U.S. FDA for the investigational drug dapagliflozin for the treatment of adults with type 2 diabetes. The FDA assigned a new Prescription Drug User Fee Act (PDUFA) goal date of Jan. 11, 2014.

Why Everyone is Talking About Glucagon

In anticipation of stable, liquid glucagon, one of the newest entrants into the insulin pump space, Tandem Diabetes Care has jumped ahead of the crowd and created a two-chamber infusion pump capable of holding and injecting both insulin and a secondary hormone, which they expect will be glucagon. This tandem Tandem pump is already being tested in Dr. Ed Damiano's clinical trial of a dual-hormone bionic pancreas.

5 Great Diabetes Apps to Help You Manage Your Health

There are almost one million apps in the iTunes store, and when you consider all the apps unique to Android phones, the choices can be overwhelming.…

Sanofi’s Lyxumia Approved for Type 2 Diabetes Treatment in Japan

Japan's Ministry of Health, Labor and Welfare (MHLW) approved the manufacturing and distribution of Sanofi's new type 2 diabetes treatment, Lyxumia (lixisenatide) in Japan. Lyxumia, the first once daily prandial GLP-1 receptor agonist (RA), is also the first GLP-1 RA approved in Japan...

First Diabetes Calculator for Kids

Nationwide Children’s Hospital recently developed an online resource to help parents manage their child’s diabetes more effectively and better…

Biodel to Produce Glucagon Rescue Product

Biodel has announced plans to submit a New Drug Application (NDA) to the FDA in 2015 for a novel glucagon rescue device to treat severe hypoglycemia. Having previously signed a long-term commercial supply agreement for bulk glucagon, Biodel expects to select a final formulation of its novel glucagon therapy...